Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.

Tseng KY, Caballero A, Dec A, Cass DK, Simak N, Sunu E, Park MJ, Blume SR, Sammut S, Park DJ, West AR.

PLoS One. 2011;6(11):e27187. doi: 10.1371/journal.pone.0027187. Epub 2011 Nov 2.

2.

Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease?

West AR, Tseng KY.

Front Syst Neurosci. 2011 Jun 30;5:55. doi: 10.3389/fnsys.2011.00055. eCollection 2011.

3.

Nitric oxide signaling in brain function, dysfunction, and dementia.

Steinert JR, Chernova T, Forsythe ID.

Neuroscientist. 2010 Aug;16(4):435-52. doi: 10.1177/1073858410366481. Review.

PMID:
20817920
4.

Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila.

Kanao T, Venderova K, Park DS, Unterman T, Lu B, Imai Y.

Hum Mol Genet. 2010 Oct 1;19(19):3747-58. doi: 10.1093/hmg/ddq289. Epub 2010 Jul 12.

PMID:
20624856
5.
6.

PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4.

Kwon IK, Wang R, Thangaraju M, Shuang H, Liu K, Dashwood R, Dulin N, Ganapathy V, Browning DD.

Oncogene. 2010 Jun 10;29(23):3423-34. doi: 10.1038/onc.2010.91. Epub 2010 Mar 29.

7.

Mechanisms underlying inflammation in neurodegeneration.

Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH.

Cell. 2010 Mar 19;140(6):918-34. doi: 10.1016/j.cell.2010.02.016. Review.

8.

Nitric oxide synthase is not essential for Drosophila development.

Yakubovich N, Silva EA, O'Farrell PH.

Curr Biol. 2010 Feb 23;20(4):R141-2. doi: 10.1016/j.cub.2009.12.011. No abstract available.

9.

JNK/FOXO-mediated neuronal expression of fly homologue of peroxiredoxin II reduces oxidative stress and extends life span.

Lee KS, Iijima-Ando K, Iijima K, Lee WJ, Lee JH, Yu K, Lee DS.

J Biol Chem. 2009 Oct 23;284(43):29454-61. doi: 10.1074/jbc.M109.028027. Epub 2009 Aug 31.

10.

Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.

Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Haque ME, Park DS.

Hum Mol Genet. 2009 Nov 15;18(22):4390-404. doi: 10.1093/hmg/ddp394. Epub 2009 Aug 19.

PMID:
19692353
11.

Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants.

Lessing D, Bonini NM.

Nat Rev Genet. 2009 Jun;10(6):359-70. doi: 10.1038/nrg2563. Review.

12.

dXNP/DATRX increases apoptosis via the JNK and dFOXO pathway in Drosophila neurons.

Hong YK, Lee NG, Lee MJ, Park MS, Choi G, Suh YS, Han SY, Hwang S, Jeong G, Cho KS.

Biochem Biophys Res Commun. 2009 Jun 26;384(2):160-6. doi: 10.1016/j.bbrc.2009.04.112. Epub 2009 May 4.

PMID:
19406101
13.

Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.

Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B.

EMBO J. 2008 Sep 17;27(18):2432-43. doi: 10.1038/emboj.2008.163. Epub 2008 Aug 14.

14.

Immunological features of alpha-synuclein in Parkinson's disease.

Roodveldt C, Christodoulou J, Dobson CM.

J Cell Mol Med. 2008 Oct;12(5B):1820-9. doi: 10.1111/j.1582-4934.2008.00450.x. Epub 2008 Jul 30. Review. Erratum in: J Cell Mol Med. 2008 Dec;12(6B):2875.

15.

Trafficking of cGMP-dependent protein kinase II via interaction with Rab11.

Yuasa K, Yamagami S, Nagahama M, Tsuji A.

Biochem Biophys Res Commun. 2008 Sep 26;374(3):522-6. doi: 10.1016/j.bbrc.2008.07.071. Epub 2008 Jul 24.

PMID:
18656450
16.

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium.

Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6.

17.

Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols.

Aquilano K, Baldelli S, Rotilio G, Ciriolo MR.

Neurochem Res. 2008 Dec;33(12):2416-26. doi: 10.1007/s11064-008-9697-6. Epub 2008 Apr 16. Review.

PMID:
18415676
18.

The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniƫls V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR.

J Biol Chem. 2008 Jun 13;283(24):16906-14. doi: 10.1074/jbc.M708718200. Epub 2008 Apr 8.

19.

Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.

Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB.

Mol Carcinog. 2008 Jul;47(7):519-25. doi: 10.1002/mc.20409.

PMID:
18163459
20.

A GluR1-cGKII interaction regulates AMPA receptor trafficking.

Serulle Y, Zhang S, Ninan I, Puzzo D, McCarthy M, Khatri L, Arancio O, Ziff EB.

Neuron. 2007 Nov 21;56(4):670-88.

Supplemental Content

Support Center